Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

241results about How to "Increase oxygenation" patented technology

Noninvasive measurement of chemical substances

Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system utilizes eye lid motion and / or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.
Owner:GEELUX HLDG LTD

Contact lens for collecting tears and detecting analytes for determining health status, ovulation detection, and diabetes screening

Utilization of a contact device placed on the eye in order to detect physical and chemical parameters of the body as well as the non-invasive delivery of compounds according to these physical and chemical parameters, with signals being transmitted continuously as electromagnetic waves, radio waves, infrared and the like. One of the parameters to be detected includes non-invasive blood analysis utilizing chemical changes and chemical products that are found in the conjunctiva and in the tear film. A transensor mounted in the contact device laying on the cornea or the surface of the eye is capable of evaluating and measuring physical and chemical parameters in the eye including non-invasive blood analysis. The system utilizes eye lid motion and / or closure of the eye lid to activate a microminiature radio frequency sensitive transensor mounted in the contact device. The signal can be communicated by wires or radio telemetered to an externally placed receiver. The signal can then be processed, analyzed and stored. Several parameters can be detected including a complete non-invasive analysis of blood components, measurement of systemic and ocular blood flow, measurement of heart rate and respiratory rate, tracking operations, detection of ovulation, detection of radiation and drug effects, diagnosis of ocular and systemic disorders and the like.
Owner:GEELUX HLDG LTD

Compositions and method of tissue superoxygenation

InactiveUS20030083610A1Increase tissue oxygenationPromoting efficient diffusion of oxygenAntibacterial agentsBiocideTissue oxygenDisease
Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections.
Owner:HYDRON TECH

Apparatus and method for purification of agricultural animal waste

The present invention is drawn to a unique apparatus and method for treating and reusing the wastewater discharged from agricultural animal farms. The apparatus and method of the present invention may be readily sized and configured depending upon the amount and constituent(s) of the wastewater to be treated. In a first embodiment, the apparatus and method of the present invention is designed to be a zero discharge system in which no wastewater will be discharged or spray irrigated. In use, the apparatus and method of the first embodiment may actually require addition of make-up water during periods of low rainfall to make-up water losses due to evaporation and drift. It is contemplated that the only byproduct of the apparatus and method of the first embodiment may be a beneficial sludge if a sufficient number of installations are operated. In a second embodiment, the apparatus and method of the present invention provides a treatment system capable of reducing the nutrient loading in a step-wise fashion so that the wastewater can be used from different steps of treatment in order to apply the varying nutrient loads required by crops on a seasonal basis.
Owner:AGRIMOND USA CORP

Process for operating a respirator and/or anesthesia device in the aprv mode with the %pef criterion and a device operated correspondingly

A process for operating a respirator and / or anesthesia device in the APRV mode with the % PEF criterion which includes a detection of a spontaneous expiratory effort by the patient and initiation of a pressure release phase when the detected spontaneous expiratory effort by the patient falls within a predetermined trigger window (Tfreg). A device is provided that is operated correspondingly.
Owner:DRAGERWERK AG

Method of treating cardio pulmonary diseases with no group compounds

Treatment of pulmonary disorders associated with hypoxemia and / or smooth muscle constriction and / or inflammation comprises administering into the lungs as a gas compound with an NO group which does not form NO2 / NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and / or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2 / NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.
Owner:DUKE UNIV

Prevention of tissue ischemia, related methods and compositions

Provided herein are compositions and methods for preventing, ameliorating, and / or reducing tissue ischemia and / or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and / or blocking TSP1 and / or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.
Owner:WASHINGTON UNIV IN SAINT LOUIS +1

Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN +4

Prevention of tissue ischemia, related methods and compositions

ActiveUS20100092467A1Increase blood flowIncreasing tissue oxygenationOrganic active ingredientsPeptide/protein ingredientsATHEROSCLEROTIC VASCULAR DISEASEIncreased blood flow
Provided herein are compositions and methods for preventing, ameliorating, and / or reducing tissue ischemia and / or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and / or blocking TSP1 and / or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.
Owner:WASHINGTON UNIV IN SAINT LOUIS +1

Method and apparatus for injecting sighs during the administration of continuous positive airway pressure therapy

Methods and apparatus for administering CPAP to a patient are disclosed. The method includes providing a controllable flow of gas from a source to a patient creating a continuous positive airway pressure and controlling the flow of gas so that it is periodically modified to inject a sigh cycle into the CPAP. The administration of sigh cycle inclusive CPAP is useful for the treatment of respiratory dysfunction and for stimulating the release of surfactant in immature lungs. It is preferred to monitor the airway pressure and to inject the sigh cycle when a drop in pressure is detected. The apparatus centers on a driver used in conjunction with a gas delivery. The driver includes a valve, adapted to receive gas from a source, for regulating the flow of gas to the delivery device in response to a control signal. A controller, connected to the valve, generates the control signal so that the valve periodically modifies the flow of gas, thereby injecting a sigh cycle. A sensor is connected to sense the airway pressure and generate a pressure signal representative of the airway pressure. The controller periodically modifies the flow of gas in response to this pressure signal. It is especially preferred to initiate a sigh cycle when a drop in airway pressure is sensed.
Owner:E M E ELECTRO MEDICAL EQUIP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products